Researchers explored data from nearly 2,500 AFib ablation patients, sharing their findings in JAMA Cardiology.

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.

An accidental discovery could have future implications for the material makeup for MRI contrast media.

All participants were free of ASCVD and had no history of statin use at the start of the study. 

The new technique uncovers hidden inflammation in patients who, despite undergoing extensive treatment for the condition, had worsening symptoms.

TAVR was initially associated with greater benefits than surgery, but that difference faded by the end of the first year.

Johns Hopkins researchers demonstrated the worthiness of the concept this year.

James Januzzi Jr., MD, said the treatment's overall impact was neutral, but he and his team saw "a very clear and encouraging signal."